Breaking News

Tweet TWEET

ArjoHuntleigh and Ossur Formalize Distribution Agreement to Deliver DVTCare at Home Program

ArjoHuntleigh and Ossur Formalize Distribution Agreement to Deliver DVTCare at
                                 Home Program

-- More At-Risk Patients May Benefit from the new DVTCare at Home Program --

PR Newswire

ADDISON, Ill., Nov. 12, 2013

ADDISON, Ill., Nov. 12, 2013 /PRNewswire/ -- Ossur, a leading global provider
of non-invasive orthopedic and prosthetic devices, and ArjoHuntleigh, a
leading manufacturer of medical devices, have formalized a distribution
agreement to deliver DVT prevention to patients after hospital discharge.
ArjoHuntleigh's program will utilize Ossur's new DVTCare^TM system. The
agreement marks the launch of the companies' comprehensive DVTCare at Home
program, which is intended to help reduce patients' risk of developing
deep-vein thromboses (DVTs) by using Ossur's unique, portable compression
device following their hospital discharge.

"We are pleased to be partnering with ArjoHuntleigh, a recognized market
leader in acute care DVT prevention," said Olafur Glyfson, President of Ossur
Americas. "This partnership enables us to provide our new DVT prevention
system to more patients, and should ultimately lead to both improved clinical
outcomesand reduced healthcare costs."

Each year, an estimated two million Americans are diagnosed with DVTs, a
common but serious medical condition caused by the formation of blood clots in
patients' lower limbs. ^1 The most serious side effect of DVTs is pulmonary
embolism, a deadly condition that often requires extensive patient care and
re-hospitalization, and ultimately claims an estimated 300,000 U.S. lives
annually. ^2

"We are very excited about the launch of the DVTCare at Home Program, which
extends ArjoHuntleigh's VTE prevention expertise into the post-acute care
setting," said Brian Straeb, Vice President of Marketing for ArjoHuntleigh
USA. ArjoHuntleigh's Flowtron® Active Compression Systems are among the most
frequently utilized to reduce the risk of thrombus formation in hospitalized
patients.

Clinical Bodies, Medicare Encourage DVT Prevention
Ossur's new DVTCare system has been designed to help reduce a patient's risk
of developing a DVT when they are at home and most vulnerable after discharge.
Elderly patients, and those who have undergone orthopedic surgery,
chemotherapy treatment, or otherwise experienced extended periods of
immobility are considered among the greatest at-risk for developing DVTs.

Major clinical bodies have also recognized that inappropriate inpatient and
post-discharge care may further increase an individual's risk for developing
DVTs. The U.S. Centers for Medicare and Medicaid Services (CMS) recently
classified DVTs as a "never event," considering them a serious and preventable
hospital-acquired adverse outcome. Evidence-based clinical practice
guidelines of the American College of Chest Physicians (ACCP) recommend
post-discharge use of newer battery-powered Intermittent Pneumatic Compression
Devices (IPCDs), such as the DVTCare system, to manage patient's DVT risk.

About Ossur
Ossur (NASDAQ OMX: OSSR) is a global leader in non-invasive orthopedics that
help people live a life without limitations. Its business is focused on
improving people's mobility through the delivery of innovative technologies
within the fields of braces, supports, prosthetic limbs and compression
therapy. A recognized "Technology Pioneer", Ossur invests significantly in
research and product development; its award-winning designs ensuring a
consistently strong position in the market. Successful patient and clinical
outcomes are further empowered via Ossur's educational programs and business
solutions. Headquartered in Iceland, Ossur has major operations in the
Americas, Europe and Asia, with additional distributors
worldwide.www.ossur.com

About ArjoHuntleigh
ArjoHuntleigh, a member of the Getinge AB Group, is a leading global provider
of equipment and systems that contribute to quality enhancement and cost
efficiency within healthcare and life sciences. Equipment, service and
technologies are supplied under the brands ArjoHuntleigh for patient handling
and hygiene, disinfection, DVT prevention, medical beds, therapeutic surfaces
and diagnostics, GETINGE for infection control and prevention within
healthcare and life science and MAQUET for surgical work places,
cardiopulmonary and critical care. ArjoHuntleigh offers a broad range of
integrated solutions for the care of people with reduced mobility and related
conditions, with the aim to enhance the quality of care in elderly care
facilities, hospitals and other healthcare environments. More information
about ArjoHuntleigh can be found atwww.ArjoHuntleigh.com.

Contact:
Chris Ryan, Senior Marketing Manager
ArjoHuntleigh
630.785.4537
Christopher.Ryan@ArjoHuntleigh.com

^1 Hirsh, J and Hoak, J. Management of Deep Vein Thrombosis and Pulmonary
Embolism: A Statement for Healthcare Professionals From the Council on
Thrombosis (in Consultation With the Council on Cardiovascular Radiology),
American Heart Association. Circulation. 1996; 93: 2212-2245.

^2 Tapson VF. Acute pulmonary embolism.N Engl J Med. Mar 6 2008;
358(10):1037-52.

SOURCE ArjoHuntleigh

Website: http://www.ossur.com
Website: http://www.arjohuntleigh.com